Amturnide is owned by Novartis.
Amturnide contains Aliskiren Hemifumarate; Amlodipine Besylate; Hydrochlorothiazide.
Amturnide has a total of 1 drug patent out of which 0 drug patents have expired.
Amturnide was authorised for market use on 21 December, 2010.
Amturnide is available in tablet;oral dosage forms.
The generics of Amturnide are possible to be released after 16 May, 2023.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8183295||NOVARTIS||Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic|| |
(3 months from now)
Market Authorisation Date: 21 December, 2010
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic